Pharmacodynamics and pharmacokinetics of intravenous glibenclamide in Caucasian and Chinese patients with type-2 diabetes

European Journal of Clinical Pharmacology

Volumn 55, Issue 10, 2000, Pages 721-727

  Jonsson A ^a,b   Chan, J C N ^c   Rydberg, T ^d   Vaaler, S ^e   Hallengren, B ^a   Cockram, C S ^c   Critchley, J A J H ^c   Melander, A ^f  

^a LUND UNIVERSITY   (Sweden)

^b RYHOV COUNTY HOSPITAL   (Sweden)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d The Pharmacies in Skane   (Sweden)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f Network for Pharmacoepidemiology Foundation   (Sweden)

Author keywords

Glibenclamide; Insulin; Proinsulin

Indexed keywords

GLIBENCLAMIDE; INSULIN; PROINSULIN;

ADULT; ARTICLE; CAUCASIAN; CHINESE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; ETHNIC DIFFERENCE; FEMALE; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL;

EID: 0033985587     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050004     Document Type: Article

References (31)

1. 1. Gerich JE (1998) The genetic basis of type 2 diabetes: Impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 19: 492-503
2. 2. Mako ME, Starr JI, Rubenstein AH (1977) Circulating proinsulin in patients with maturity onset diabetes. Am J Med 63: 865-867
3. 3. Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte D, Jr (1987) Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 30: 698-702
4. 4. Temple RC, Carrington CA, Luzio SD, Owens DR, Scheinder AE, Sobey WJ, Hales CN (1989) Insulin deficiency in non-insulin-dependent diabetes. Lancet 1: 293-295
5. 5. Fujimoto WY (1996) Overview of non-insulin dependent diabetes mellitus (NIDDM) in different population groups. Diabet Med 13: S7-S10
6. 6. Arner P, Pollare T, Lithell H (1991) Different etiologies of type 2 (non-insulin-dependent) diabetes mellitus in obese and non-obese subjects. Diabetologia 34: 483-487
7. 7. Ramachandran A, Snehalahta C, Dharmaraj D, Viswanathan M (1992) Prevalence of glucose intolerance in Asian Indians. Diabetes Care 15: 1348-1355
8. 8. Mather HM, Keen H (1985) The Southall Diabetes Survey: Prevalence of known diabetes in Asians and Europeans. BMJ 291: 1081-1084
9. 9. Chan JCN, Cockram CS (1997) Diabetes mellitus in Chinese and its implications on health care. Diabetes Care 20: 1785-1790
10. 10. Knowler WC, Bennett PH, Hamman RF, Miller M (1978) Diabetes incidence and prevalence in Pima Indians: A 19-fold greater incidence than in Rochester, Minnesota. Am J Epidemiol 208: 497-505
11. 11. UK Prospective Diabetes Study Group (1994) UK Prospective Diabetes Study XII: Differences between Asian, Afro-Carribean and White Caucasian type 2 diabetic patients at diagnosis of diabetes. Diabet Med 11: 670-677
12. 12. Hosker JP, Burnett MA, Davies EG, Harris EA, Turner RC (1985) Sulphonylurea therapy doubles B-cell response to glucose in type 2 diabetic patients. Diabetologia 28: 809-814
13. 13. Groop LC, Barzilai N, Ratheiser K, Luzi L, Wåhlin-Boll E, Melander A, DeFronzo RA (1991) Dose-dependent effects of glyburide on insulin secretion and glucose uptake in humans. Diabetes Care 14: 724-727
14. 14. Duckworth WC, Kitabchi AE, Heinemann M (1972) Effect of chronic sulfonylurea therapy on plasma insulin and proinsulin levels. J Clin Endocrinol Metab 35: 585-589
15. 15. Von Hausmann L, Schumann G, Kaffarnik H (1978) Untersuchungen zur insulin-und proinsulinsekretion nach intravenöser gabe von tolbutamid, glisoxepid und glibenklamid. Arzneimittelforschung 28: 83-86
16. 16. Elkeles R, Heding L, Paisey R (1982) The long-term effects of chlorpropamide on insulin, C-peptide and proinsulin secretion. Diabetes Care 5: 427-429
17. 17. Wood AJJ, Zhou HH (1991) Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 20: 350-373
18. 18. Taylor AR, Brownsill RD, Grandon H, Lefoulon F, Petit A, Luijten W, Kopelman PG, Walther B (1996) Synthesis of putative metabolites and investigation of the metabolic rate of gliclazide in diabetic patients. Drug Metab Dispos 24: 55-64
19. 19. Birkeland KI, Torjesen PA, Eriksson J, Vaaler S, Groop L (1994) Hyperproinsulinemia of type 2 diabetes is not present prior to the development of hyperglycemia. Diabetes Care 17: 1307-1310
20. 20. Lindström T, Arnqvist HJ, Von Schenck HH (1992) Effects of conventional and intensified insulin therapy on free-insulin profiles and glycemic control in NIDDM. Diabetes Care 15: 27-34
21. 21. Rydberg T, Wåhlin-Boll E, Melander A (1991) Determination of glibenclamide and its two major metabolites in human serum and urine by column liquid chromatography. J Chromatogr 564: 223-233
22. 22. Galloway J, Hoope S, Spradlin T, Howey D, Frank B, Bowsher R, Anderson J (1992) Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience. Diabetes Care 15: 666-692
23. 23. Rachman J, Levy JC, Barrow BA, Manley SE, Turner RC (1997) Relative hyperproinsulinemia of NIDDM persists despite reduction of hyperglycaemia with insulin or sulfonylurea therapy. Diabetes 46: 157-162
24. 24. Kumakura S, Iwamoto Y, Kuzuya T, Shiraishi I, Matsuda A, Saito T (1995) Elevated ratio om summed serum proinsulin to insulin response after oral glucose load in type 2 diabetes decreases following sulfonylurea treatment. Diabetes Res Clin Pract 29: 107-112
25. 25. Prigeon RL, Jacobson RK, Porte D, Jr, Kahn SE (1996) Effect of sulfonylurea withdrawal on proinsulin levels, B cell function, and glucose disposal in subjects with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 81: 3295-3298
26. 26. Davies MJ, Metcalfe J, Day JL, Grenfell A, Hales CN, Gray IP (1994) Effect of sulphonylurea therapy on plasma insulin, intact and 32/33 split proinsulin in subjects with type 2 diabetes mellitus. Diabet Med 11: 293-298
27. 27. Zhou HH, Koshajaki RP, Silberstein DJ, Wilkinson GR, Wood AJJ (1989) Racial differences in drug response, altered sensitivity and clearance of propranolol in men of Chinese descent as compared with American Whites. N Engl J Med 320: 565-570
28. 28. Zhou HH, Wilkinson GR (1990) Differences in plasma binding of drugs between Caucasians and Chinese subjects. Clin Pharmacol Ther 48: 10-17
29. 29. Horai Y, Nakano M, Ishizaki K, Zhou HH, et al. (1989) Metoprolol and mephenytoin oxidation polymorphism in far eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 46: 198-207
30. 30. Peart GF, Boutagy J, Shenfield GM (1989) The metabolism of glyburide in subjects of known debrisoquin phenotype. Clin Pharmacol Ther 45: 277-284
31. 31. Dahl-Pustinen M-L, Alm C, Bertilsson L, Christensson I, Östman J, Thunberg E, Wikström I (1990) Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes. Br J Clin Pharmacol 30: 476-480